Prediction of dose reductions and impact of reduced starting doses of CDK4/6i on effectiveness in HR-positive/HER2-negative metastatic breast cancer: Real-world data from the OPAL registry.
- DOI
- 10.1002/ijc.70433
- Published
- 2026 Jul 1
- Container
- International journal of cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/ijc.70433,
title = {Prediction of dose reductions and impact of reduced starting doses of CDK4/6i on effectiveness in HR-positive/HER2-negative metastatic breast cancer: Real-world data from the OPAL registry.},
author = {Marschner P and Ringwald K and Thill M and Zahn MO and Welt A and Nusch A and Kaltenecker G and Rodemer Y and Hagen V and Schock C and Kruggel L and Kaiser-Osterhues A and Klein D and Haug N and Stickeler E and Harbeck N and Wöckel A and Marschner N and Decker T and OPAL Registry Group},
year = {2026},
journal = {International journal of cancer},
doi = {10.1002/ijc.70433},
url = {https://doi.org/10.1002/ijc.70433}
}RIS
TY - JOUR TI - Prediction of dose reductions and impact of reduced starting doses of CDK4/6i on effectiveness in HR-positive/HER2-negative metastatic breast cancer: Real-world data from the OPAL registry. AU - Marschner P AU - Ringwald K AU - Thill M AU - Zahn MO AU - Welt A AU - Nusch A AU - Kaltenecker G AU - Rodemer Y AU - Hagen V AU - Schock C AU - Kruggel L AU - Kaiser-Osterhues A AU - Klein D AU - Haug N AU - Stickeler E AU - Harbeck N AU - Wöckel A AU - Marschner N AU - Decker T AU - OPAL Registry Group PY - 2026 JO - International journal of cancer DO - 10.1002/ijc.70433 UR - https://doi.org/10.1002/ijc.70433 ER -
APA
P, M., K, R., M, T., MO, Z., A, W., A, N., G, K., Y, R., V, H., C, S., L, K., A, K., D, K., N, H., E, S., N, H., A, W., N, M., T, D., & Group, O. R. (2026). Prediction of dose reductions and impact of reduced starting doses of CDK4/6i on effectiveness in HR-positive/HER2-negative metastatic breast cancer: Real-world data from the OPAL registry.. International journal of cancer. https://doi.org/10.1002/ijc.70433
Source records
- pubmed · retrieved 2026-09-25T07:31:39.703Z